Anebulo Pharmaceuticals is a Texas-based biotechnology company dedicated to developing and selling treatments for acute cannabinoid intoxication and substance addiction. They are focused on their lead product, ANEB-001, which is a small molecule cannabinoid receptor antagonist aimed at treating cannabinoid intoxication and overdose. Anebulo Pharmaceuticals was established in 2020, and it is currently in the clinical stage of development.